Free Access
| Issue |
Med Sci (Paris)
Volume 20, Number 8-9, Août-Septembre 2004
|
|
|---|---|---|
| Page(s) | 750 - 751 | |
| Section | Nouvelles | |
| DOI | https://doi.org/10.1051/medsci/2004208-9750 | |
| Published online | 15 August 2004 | |
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344 : 1031–7. [Google Scholar]
- Hill C, Doyon F. Frequency of cancer in France : 2004 update. Bull Cancer 2004; 91 : 9–14. [Google Scholar]
- IALT. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350 : 351–60. [Google Scholar]
- Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346 : 92–8. [Google Scholar]
- Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003; 284 : 122–30. [Google Scholar]
- Fayette J, Soria JC. Thérapies moléculaires ciblées : l’exemple de l’Iressa® (ZD1839). Med Sci (Paris) 2003; 19 : 1052–4. [Google Scholar]
- Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer : a randomized trial. JAMA 2003; 290 : 2149–58. [Google Scholar]
- Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21 : 2237–46. [Google Scholar]
- Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer : a phase III trial-INTACT 2. J Clin Oncol 2004; 22 : 785–94. [Google Scholar]
- Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer : a phase III trial-INTACT 1. J Clin Oncol 2004; 22 : 777–84. [Google Scholar]
- Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350 : 2129–39. [Google Scholar]
- Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science 2004; 304 : 1497–500. [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.